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Abstract
Antiphospholipid syndrome which is also known as APS is an autoimmune 
disease which represents an acquired form of thrombophilia. The etiology of APS 
remains unknown. This disorder occurs when the immune system mistakenly 
attacks some of the normal human proteins and manifests itself as recurrent arterial 
or venous thrombosis and it could emerge after abortions or in recurrent pregnancy 
loss. In APS, the body produces the wrong antibodies against phospholipid-binding 
proteins, that is present in the blood and plays an important role in coagulation. 
Antibodies are specific proteins that usually target and neutralize the body’s invad-
ers, such as viruses and bacteria. When antibodies attack phospholipid-binding 
proteins, blood clots abnormally. Specifically, it could cause blood clots in veins or 
arteries leading to stroke and various pregnancy complications such as: endometrial 
death, miscarriage, preeclampsia, intrauterine growth restriction and prematurity. 
APS is divided into primary and secondary, which is associated with autoimmune 
diseases and more often with systemic lupus erythematosus (SLE), while antibodies 
against cardiolipin are detected in many other conditions (infections, malignancies, 
drugs, etc.). The symptoms of APS, in addition to arterial and/or venous thrombo-
sis and pregnancy complications, are multisystemic and the differential diagnosis of 
the primary APS from the secondary, in the context of SLE, is of particular clinical 
interest and is subject of this literature review.




APS characterized by thrombosis of the arteries, veins and microvessels and/or 
with pregnancy morbidity, with persistently elevated antiphospholipid antibody 
(aPLs) titers. The syndrome was first described in 1983 by Professor G. Hughes, at 
Hammersmith Hospital (Hughes Syndrome) [1, 2]. APS is a prothrombotic condi-
tion (with related complications such as deep vein thrombosis, pulmonary embo-
lism, etc.), belonging to autoimmune diseases of unknown cause, and is strongly 
associated with pregnancy [1–3]. Generally, autoimmune diseases namely Sjorgen’s 
syndrome, Spondylanthritis, rheumatoid arthtritis RA have an incidence of 5–8% 
in the general population organoid or systemic, and represent the 2nd cause of 
hospitalization in Internal Medicine Departments and the 3rd cause of morbidity/
mortality [1–4]. APS occurs as primary in the absence of findings of other autoim-
mune diseases or as secondary in 36% of cases in the context of another autoim-
mune disease (SEL, Sjogren’s disease, inflammatory bowel disease, etc.), while it 
is present in about 5% of patients with subclinical SEL or coexists with another 
underlying systemic autoimmune disease in 6% of cases [5, 6].
2. Epidemiology
The incidence of the syndrome is increased with age. During pregnancy, aPLs 
detection ranges from 0 to 11%, with an average incidence of about 2%. On the 
contrary, the syndrome is detected in up to 37% of the patients with systemic 
erythematosus lupus (SEL). In the nonpregnancy setting, venous thromboses are 
more common than arterial ones and can be diagnosed by imaging techniques and/
or histologic evidence [5–7].
3. Frequency
According to literature APS is the cause for 1 out of 5 Deep Vein Thrombosis 
(‘DVTs’), 1 out of 5 cases of SLE (arterial stroke) in young patients (age <45 years) 
and 1 out of 5 miscarriages. Especially for Obstetrics Hughes Syndrome is currently 
recognized as the leading cause for the miscarriages [5–7]. In addition, APS is diag-
nosed as the underlying diagnosis in a still unknown percentage of cases previously 
misdiagnosed as migraine, Alzheimer’s disease, and Multiple MS. It is estimated 
that the true incidence of the syndrome can be up to 1–2% or more in the general 
population [5–7]. Correlations-Percentages The mean age of APS onset is >30 years, 
with a female to male ratio of 5:1 and relapses usually take place at the same or 
similar area of the body. There is no apparent racial preference, but an increased 
incidence of SEL is reported in African Americans and Spaniards. Patients with SEL 
have positive aPLs in a percentage of 15–35%, but only about 50% of these patients 
will develop APS symptoms [5–7].
4. Clinical subtypes
Special categories of APS are described usually correlated to the target-organ 
or the severity of the manifestations. The following are included: Generalized 
APS, Arterial APS, APS and heart, APS and kidneys, Cerebral APS, Pediatric APS, 
Neonatal APS, Catastrophic CAPS and Obstetric APS [5–7].
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5. Catastrophic APS
The 0.8% of the cases is characterized as Catastrophic Antiphospholipid 
Syndrome (CAPS). It is a very rare and severe form of APS. There are diffuse 
clots in the small vessels throughout the body. Sometimes it can appear as the first 
manifestation of APS and even without clinical or serological confirmation of 
SEL. Early diagnosis is necessary and immediate start of an aggressive treatment is 
inevitable [5, 7–9]. CAPS is caused when at least 3 different systems are affected at 
intervals of days or weeks, with multiple thrombosis in large and small vessels. The 
organs that are usually affected are: a) kidneys, b) lungs, c) heart, d) small-large 
vessels with consequences as peripheral limb ischemia, stroke, myocardial infarc-
tion, thrombosis of blood vessels of abdominal organs with a mortality rate of 50% 
[5, 7–9]. The observed thrombocytopenia is usually mild between 100-150x109/L 
but severe thrombocytopenia can be also observed. The prevalence of the syndrome 
in the general population ranges between 2% and 4% meaning 40–50 patients in 
100,000 based on the criteria (mean age of diagnosis 34 years) and 7: 1 in the SEL/
APS combination [5, 7–9].
6. Therapeutic interventions for catastrophic APS
Anticoagulant therapy + corticosteroids.
Anticoagulant therapy + corticosteroids + plasmapheresis.
Anticoagulant therapy + corticosteroids + IV γ-globin.
Anticoagulant therapy + corticosteroids + plasmapheresis + IV γ-globulin.
Diffuse intravascular coagulation is not usually seen in primary or secondary 
APS but it occurs in about 25% of patients with catastrophic APS. It is estimated 
that more than 53% of cases are related to the primary syndrome. It is estimated 
that approximately 10% of patients with primary APS will be diagnosed with 
another autoimmune, disorder, such as SEL, at some point in their lives which is 
estimated to coexist in up to 37% of patients with APS. Patients with primary APS 
and a female/male ratio incidence of 3.5: 1 should not be classified as SEL patients, 
as they are two different disease entities [5, 7–9]. Also, aPLs found in a variety of 
rheumatic and autoimmune diseases should not be confused with APS. The latter 
includes autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, 
rheumatoid arthritis and cutaneous manifestations such as edema. Also, the same 
antiphospholipid antibodies are detected either temporarily or permanently after 
various infections, such as hepatitis A, hepatitis B, acquired immune deficiency 
(AIDS), mumps, toxoplasmosis, erythema etc. The use of certain medicines, such 
as hydralazine, procainamide, and amoxicillin, phenothiazines may cause a serious 
differential diagnosis with APS, which requires immediate diagnostic and thera-
peutic treatment to reduce the increased maternal risk, and in particular perinatal 
morbidity and mortality due to placental infarction [5, 7–9].
7. Pathophysiology
Dysfunction of the vascular epithelium as well as oxidative damage and modi-
fications of phospholipid-bound proteins that interfere with the regulation of 
coagulation are possible. It occurs when the immune system mistakenly attacks 
some of the normal proteins in the blood. The mechanism by which aPLs causes 
thrombosis is not fully understood. APLs consist of a heterogeneous group of 
Inflammation
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autoantibodies that react primarily with plasma proteins associated with negatively 
charged phospholipids (epitope formation). Moreover, also react directly with both 
phospholipid-binding proteins and phospholipids [10–12].
However, aPLs have been shown to target not only cell membrane phospholipids, 
but also plasma proteins. Initially aPLs are directed directly against negative cell 
membrane phospholipids and autoantibodies are directed against plasma proteins with 
high affinity for these anionic phospholipids [10–14]. Phospholipids are like building 
blocks of cell membranes and the appearance of aPLs is due to the “projection” of their 
anions to the extracellular space [10–14]. This phenomenon is usually happening due 
to various causes, such as trauma, ischemia, inflammation, infections, or drug interac-
tions. They were first observed in 1906 in 1–5% of the normal population.
The prevailing theory is that APS initially causes a disorder in cell apoptosis 
procedure resulting in the exposure of cell membrane phospholipids and their 
subsequent binding to various plasma proteins, such as β2-glycoprotein I. This 
binding leads, through activation, to generation of intracellular mediators (such as 
nuclear factor kappa B and mammalian target of rapamycin), and the formation of 
a phospholipid-protein complex resulting in the discovery of a new epitope, which 
then becomes target of autoantibodies [10–14].
Recent studies suggest that oxidized β2-glycoprotein I is capable of binding to 
and subsequently activating dendritic cells in a similar pathway to the one induced 
by activation via the Toll-like receptor 4 (TLR-4), resulting in its induction and the 
production of autoantibodies.
A total of 4 types of aPLs have been isolated [14–18].
1. Antibodies that give a false positive serological test for syphilis.
2. Lupus anticoagulants, which are antibodies to plasma proteins that bind to 
anionic phospholipids and cause prolonged results in laboratory methods of 
coagulation control, such as activated partial thromboplastin time (aPTT), 
kaolin clotting time (Kaoline Clotting)-KCT) and dilute Russell Viper Venom 
Time (dRVVT). These proteins are prothrombin or annexin V [14–18].
3. Antibodies to cardiolipin and phosphatidylserine. These antibodies may be 
IgA, IgG or IgM and may cross-react with lupus anticoagulants.
4. Antibodies to β2-glycoprotein-I, which are detected in a significant percentage 
of patients with primary or secondary antiphospholipid syndrome, while in 
11% of patients it is the only laboratory finding [14–18]. This association results 
in either the discovery of “hidden” antigenic epitopes or the creation of new or 
simply increasing the concentration of weak antigenic sites in such quantities 
as to elicit an immune response.
Types of anti-b2 GPI antibodies [14–18]. There are several types of anti-β2 gly-
coprotein I antibodies, but not all of them are harmful. Those that target specific β-2 
glycoprotein epitopes, such as the epitope in the N-terminal I domain of the molecule, 
are associated with the onset of clinical manifestations of the syndrome [14–18].
8.  Correlation between APS clinical events and the type of anti-β2GPI 
antibodies
Patients with triple positivity in aPLs: have higher anti-β2GPI – domain I 
antibody titles, compared to patients with single or double positivity. Almost all 
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anti-β2GPI – domain I IgG antibodies tested positive after 12 weeks, in contrast to 
innocent transient aPLs, which appear to be immune to infections. Although anti-
β2GPI-Domain 1 (β2GPI-D1) IgG antibodies have been associated with thrombosis 
and pregnancy morbidity in APS patients, these antibodies are found in only one 
third of the patients [14–18].
9. Cell β2GPI/anti-β2GPI antibody receptors
Annexin A2 and Toll-like receptor (TLR) 4 are receptors for the entire β2GPI 
molecule. However, the absence of both of these receptors does not lead to the com-
plete inhibition of the binding of the anti-β2GPI antibody, a finding that supports 
the view that there are additional surface adhesion molecules that play a role. TLR1, 
TLR2 and TLR6 are potential cell receptors [14–18].
10. Association of APS with pathogenic intestinal bacteria
Β2GPI binds to LPS via domain V. Presence of a large amount of LPS prob-
ably increases the vascular distribution of APLs, by increasing the expression of 
TLR2 and especially TLR4. Because the main source of LPS in healthy people is 
the gut, it is possible that the presence of gut microbes in the gut increases them. 
Administration of intestinal flora-specific antimicrobial therapy to experimental 
animals showed a reduction in the thrombotic manifestations of APS [14–18].
11. The role of the complement in the pathogenesis of APS
Immediate evidence: In experimental models with C6-deficient rats and 
C5-depleted mice, it was shown that the addition of monoclonal anti-domain I 
MBB2 did not induce thrombosis or miscarriage. C4d and C3b sections have also 
been found in deposits on the placenta of women with APS [14–18].
Indirect evidence: In-vivo studies of the efficacy of drugs with C5 action. The 
non-complement-fixing anti-domain I monoclonal MBB2 [DELTA] Ch2 and the 
complement inhibitor C5-inhibitor rEV576 prevented the thrombotic complications 
of APS in vivo in experimental animals.
12. APL action mechanisms
APLs activate endothelial cells resulting in the expression of adhesion molecules 
(such as intercellular cell adhesion molecule-1 ICAM-1, vascular cell adhesion mol-
ecule-1 VCAM-1, E-selectin), and ultimately the overproduction of tissue factor TF.
APLs activate monocytes and cause increased tissue factor expression.
APLs activate platelets resulting in increased glycoprotein 2b-3a expression and 
thromboxane A2 synthesis. It has also recently been shown that aPLs induce the 
release of NETs from endothelial cells and these in turn further activate platelets. 
Their presence is enhanced by other conditions such as neoplasms, myelodysplastic 
syndromes, paraproteinemias, etc. [14–18].
These proteins (aPLs) normally bind to the phospholipid components of mem-
branes and protect against activation of coagulation mechanisms. Autoantibodies 
displace these “protective” proteins and promote the formation of clots in the 
cells of the vascular endothelium resulting in arterial and venous thrombosis. 
Inflammation
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In particular, aPLs antibodies include antibodies to Lupus Anticoagulant (LA), 
antibodies to cardiolipin (aCL), antibodies to β2GPI (αβ2GPI) and antibodies to 
other phospholipid-binding proteins and other phospholipids. LA, aCL and αβ2GPI 
antibodies are important in the diagnosis of antiphospholipid syndrome [12–18].
13. The most likely explanation for the pathogenesis of APS
They occur in people with a genetic predisposition after accidental exposure 
to infectious agents or in a rheumatic disease environment such as SEL. It is the 
“second hit” theory required for the full development of the syndrome. Of course, 
not all people with antiphospholipid antibodies have thrombosis or obstetric 
complications.
Τhe “two-hit theory” has been proposed, i.e. that in the manifestation of the dis-
ease only the presence of antiphospholipid antibodies is not sufficient but a second 
thrombotic risk factor must coexist (e.g. age, hypertension, infection, inflammation, 
diabetes mellitus, obesity, smoking, pregnancy and obstetrics, surgery, etc.) [14–18].
Regarding the pathophysiology of obstetric complications, trophoblast and per-
ishable blood vessel thrombosis is at the heart of this process. Various mechanisms 
have been proposed that lead to this result:
1. aPLs bind to Αnnexin V molecules and reduce the active levels of the protein in 
the blood. Annexin V is a protein that covers the negatively charged phospho-
lipids of the cell membrane when exposed to the extracellular space, thus mak-
ing it impossible to activate the thrombosis mechanism, which would occur 
under other conditions. The reduction of the levels of this protein activates the 
thrombosis of the small vessels of the trophoblastic villi and consequently the 
abnormal penetration of the trophoblast into the myometrium.
2. aPLs may reduce the levels of endogenous anticoagulant proteins C and S.
3. aPLs can bind to and activate endothelial cells. This results in the production of 
cellular inflammatory agents (VCAM-1, ICAMP1, E-selectin), which eventu-
ally attract monocytes to the area, which contribute to the production of clots 
and the apoptosis of endothelial cells.
4. Binding of aPLs to the cell membrane β2-glycoprotein-1 complex and phos-
pholipids reduces the efficacy of this complex, as an anticoagulant.
5. Binding of aPLs to platelet cell membrane components, such as phosphatidyl-
serine, results in their injury, which promotes their adhesion and activation of 
the prothrombotic chain. Finally, the activation of the complement seems to 
play an important role in the pathophysiological chain of events, which may 
be necessary in those processes that lead to fetal death or intrauterine growth 
retardation [14–18].
14. Diagnostic criteria
“APL profile” includes: the type of autoantibodies and the presence of 2–3 types 
of autoantibodies. The title of aPLs is mid-high instead of low and their persistent 
positivity is certified by multiple tests. APS is characterized by the following lab test 
results [19–22].
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Persistent presence of antiphospholipid antibodies (at least 2 positive results 
during a period of >12 weeks) including lupus anticoagulant, anticardiolipin 
antibodies and b2-glycoprotein 1α antibodies [19–22].
Risk factors: pregnancy, labour, contraceptives, malignancy, infection (E-coli, 
Shigella, Salmonella, Streptococcus, Staphylococcus etc), injury, surgical proce-
dures, operations, fractures, drugs, no compliance to the anticoagulant therapy and 
many other factors [19–22].
15. Laboratory findings
Usually there is severe thrombocytopenia, positive direct Coombs, microan-
giopathic hemolytic anemia, DIC findings in some patients and the presence of a 
heterogeneous group of antiphospholipid antibodies.
Laboratory confirmation is done with clotting assays for the detection of lupus 
anticoagulant and with solid phase assays-Elisa for the detection of anti-cardiolipin 
and anti-β2 glycoprotein antibodies [19–24].
1. The positive ACA IgG, Wolf Anticoagulant, ANA, ds-DNA, ENA (Ro, La) 
etc. are a heterogeneous group of IgG/IgM antibodies directed against plasma 
proteins involved in coagulation cataract activation. They are attached to PLs 
of the outer membrane of cells. While these antibodies cause thrombosis in 
vivo, in vitro prolong phospholipid-dependent coagulation tests. Detection 
of lupus anticoagulant (coagulation tests – 3-step procedure) prolongs the 
phospholipid-dependent coagulation time. Lupus anticoagulant is considered 
positive when it is detected in at least one of the two methods with the follow-
ing diagnostic criteria – steps:
15.1 The screening test
a. Screening procedure when prolongation is observed in at least one of the 
phospholipid-dependent coagulation methods
• Activated partial thromboplastin time (aPTT),
• Russel snake venom dilution time (dRVVT)
b. Mixing patient plasma 50:50 with normal plasma fails to correct prolonged 
screening test time
• Confirmation of the presence of coagulation inhibitor and not the absence 
of coagulation factor mixing test: Proof that the prolongation is due to the 
presence of coagulation inhibitor.
c. The addition of extra phospholipids corrects the prolonged clotting time. 
Confirmation test: Evidence that this inhibitor is directed against  
phospholipids [19–24].
15.2 Anti-cardiolipin antibodies (aCL) (IgG-IgM)
Presence of antibodies against cardiolipin (aCL) – IgG moderately to strongly 
positive (>15–20GPL) – IgM(> 15 – 20MPL) moderate to strongly positive, but with 
the simultaneous presence of LA [19–24].
Inflammation
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They are directed against epitopes resulting from modulatory changes in the 
β2GPI (domains-V) molecule after binding to cardiolipin. They are directed directly 
against cardiolipin (CL). They are associated with infections, syphilis, in healthy 
individuals and are not related to APS [19–24].
15.3 Antiβ2 GPI antibodies (IgG-IgM)
Antibodies against β2GPI (anti-β2GPI), β2-glycoproteinI (β2 GPI) natural 
anticoagulant plasma protein associated with negatively charged molecules: 
phospholipids, heparin, lipoproteins (oxLDL), activated PLTs/Ecs, apoptotic cell 
membranes.
They turn directly against β2-GPI and are a heterogeneous population that 
recognizes epitopes in different regions (I-V) of the protein.
Antigen: purified human β2GPI with tight adhesion to plates for low avidity 
binding of antibodies and detection of domain I in situ.
Anti-LA/β2GPIs are positively associated with a particularly increased risk 
of thromboembolic complications and detection with new methods offers new 
opportunities for risk assessment [19–22].
ELISA: αCL/β2GPI detects various antibody specificity es with relatively low 
clinical utility – their exclusion from the criteria has been widely discussed, they 
are still a diagnostic criterion but current screening guidelines should be followed 
faithfully [19–22].
aβ2GPI antibodies: correlate very well with the clinical manifestations of APS – 
They are positive in patients with thrombosis who have negative LA and aCLs.
If aPL title > 40 GPL or IU at least 2 times in 12 week interval then APS is 
diagnosed. The most important are Abs against β2GPI and against prothrombin 
which show LA activity. Lupus anticoagulant is part of the APS antibody spectrum, 
reacting in the liquid phase. In contrast, other aPLs such as anti-CL and anti-β2-
glycoprotein (β2-GPI-1) antibodies are detected by solid-phase immunoassay. For 
the APS diagnosis it is necessary to use both solid phase methods and coagulation 
tests for LA [19–24].
16. Other aPLs
Prothrombin antibodies: They have good association with LA, use in  
seronegative APS.
Antibodies to Annexin V, II Associated with thrombosis in APS.
Proteins against protein C and S: Lower sensitivity and specificity than 
aCLs/IgG.
Antibodies against vimentin (anti-Vim/CL: Positive (55%) in seronegative 
SN-APS, their use needs documentation.
The diagnosis of the syndrome should be avoided when a period of <12 weeks or 
> 5 years separates the clinical from the laboratory characteristics (regardless of the 
most presented first) [24–26].
17. Secondary antibodies in APS
• IgA anticardiolipin antibodies
• anti-β2 glycoprotein I IgA antibodies
9





• antibodies against the phosphatidylserine-prothrombin complex
APLs are a very heterogeneous family of antibodies and more than 30  
different antibodies have been reported in patients with APS called ‘antibody 
burst’. Their positivity does not offer much in the absence of clinical  
findings although confirmation is necessary for the duration of the  
symptoms. Ultimately the history and clinical picture determine the treatment 
[24–28].
• Presence of positive lupus anticoagulant (LA) in plasma, in at least two tests 
with an interval of at least 12 weeks between them offers reliable criteria for 
diagnosis.
• Moderate presence of high title of anticardiolipin antibodies (aCL) IgG or IgM 
in serum or plasma (eg> 40 IgG phospholipid units-GPL/mL or IgM phos-
pholipid units-MPL/mL or> 99th percentile) in at least two intervals between 
them for at least 12 weeks.
• Moderate presence of high titer anti-beta-2 glycoprotein I IgG or IgM antibod-
ies in plasma or serum (> 99th percentile) in at least two tests with an interval 
of at least 12 weeks [19–26].
• Extension Activated partial thromboplastin time (aPTT)
• Falsely positive test for syphilis
• Low levels of total protein S
• Hemolytic anemia. It occurs quite frequently and is particularly associated 
with the presence of anticardiolipin IgM antibodies
• Thrombopenia. It is quite common in patients with APS (22% at diagnosis, 
30% overall) and is associated with paradoxical thrombosis even with low 
platelet counts. It is of course possible that when their number is <50,000/μL 
there is a coexistence risk of bleeding, making the treatment of these patients 
particularly difficult and urgent.
Positive antinuclear antibodies are often found at low titers, without necessarily 
being associated with the presence of SLE [19–26].
Coagulation methods for detecting anticoagulant lupus are affected by  
oral anticoagulant therapy (coumarin, newer anticoagulants), but also by thera-
peutic doses of standard heparin. For this reason, testing should be done  
before starting or after cessation of these drugs. In contrast, administration  
of low molecular weight heparin in prophylactic doses of aspirin or clopidogrel 





APS is diagnosed in up to 40% of women with a history of miscarriage, intra-
uterine fetal death (> 18th week of gestation) or placental vascular disease, ie 
preeclampsia, intrauterine fetal growth retardation, placental abruption. However, 
in a percentage of 50–60% the causes remain unclear [26–34].
18.2 Manifested clinically with
• recurrent vascular thrombosis (venous and/or arterial, and/or capillary), 
and/or with
• obstetric vascular complications:
• abortions <10th week of pregnancy
• delayed miscarriages
• endometrial death
• preeclampsia and/or eclampsia, or HELLP syndrome
• intrauterine growth restriction (IUGR) [26–38]
18.3 Obstetric antiphospholipid syndrome triggered in pregnancy
The findings of some studies raise the suspicion of a subtype triggered by  
gestational APS, with a transient increase in antiphospholipid antibodies only  
during pregnancy.
18.4 Pregnancy morbidity
The morbidity of pregnancy is certified by the following parameters:
1. ≥1 unexplained fetal death > 10th week (morphologically healthy fetus)
2. ≥1 preterm birth <34th week (preeclampsia or severe placental insufficiency)
3. ≥3 consecutive miscarriages <10th week after exclusion of other pathologies 
such as anatomical, hormonal, chromosomal abnormalities, history of throm-
boembolic episodes
• at least 1 unexplained fetal death in the 2nd or 3rd quarter (> 10 W)
• at least 1 birth at gestational age <34 W, due to preeclampsia or placental 
insufficiency
According to the International Consensus Criteria of 2006, any of these anti-
bodies, if tested positive in at least two laboratory tests at least 12 weeks apart, 
in combination with a clinical thrombosis or obstetric complication, leads to the 
diagnosis of APS.
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There must be at least one laboratory and one clinical criterion for the diagnosis 
of primary APS. Antiphospholipid antibodies are detected by the enzyme-linked 
immunosorbent assay (ELISA) in which the phospholipid cardiolipin is used as 
the antigen. It is actually a complex of cardiolipin with a serum protein called 
β2-glycoprotein I (β2-GPI). The above protein plays an inhibitory role in blood clot-
ting, and when the complex binds to antiphospholipid antibodies, its effectiveness 
as an anticoagulant decreases [26–42].
Laboratory findings usually show high titers of IgG or IgM antibodies against 
cardiolipin or lupus anticoagulant, which must be detected in the same patient in 
two different samples taken at least 6 weeks apart. The above mechanism is due to 
the frequent recurrent thrombi that affect both the large and small vessels of the 
arterial or venous limb. In addition, mild cytopenia occurs quite often, which usu-
ally subsides with the end of pregnancy.
18.5 The diagnosis of the syndrome can be suspected in
Arterial or venous thrombosis.
Presence of anticardiolipin antibodies, IgG, IgM, Anti-beta2-GPI and Lupus 
anticoagulant [26–42].
Adverse outcomes of pregnancy.
APS can be diagnosed, if one or more of the clinical criteria and one or more of 
the laboratory criteria are met.
Although a causal association between obstetric complications and antibody 
detection is difficult to identified, however the lupus anticoagulant is the major pre-
dictor of labor adverse events including both mother and fetus. Although spontane-
ous abortions before the 10th week are relatively common in the general population, 
it seems that this risk is higher in patients with the syndrome. Fetal demise due to 
insufficient blood flow is most probably caused by placental insufficiency triggered 
by placental infarctions [26–42].
This placental insufficiency is likely to be associated with delayed intrauterine 
fetal development, severe preeclampsia, premature rupture of the membranes, 
premature placental abruption, and preterm fetal death (preterm and preterm 
death) in the 20th week of pregnancy, which usually has the worst outcome, as well 
as the increased risk of premature ejaculation [26–42].
Regarding the relationship of aPLs with preeclampsia, their detection seems 
valuable only in cases of severe preeclampsia before the 34th week of pregnancy. 
For cases of severe intrauterine fetal growth retardation, there are studies that 
report its relationship to the presence of antibodies, while other studies do not seem 
to reach this conclusion.
19. Discussion
The risk of miscarriage in women with antiphospholipid antibodies is higher 
from the 10th week of pregnancy onwards. But also in women with a history of six 
miscarriages before the 10th week of pregnancy, antiphospholipid antibodies are 
detected in rates of 10 to 20% without the presence of other clinical manifestations 
[42–44].
Pregnancy complications in women with APS are due to decreased placental 
perfusion based on local thrombosis, which is probably caused by the interaction 
of aPL with annexin V of the trophoblast resulting in inhibition of its anticoagu-
lant activity. Other manifestations of aPL include thrombocytopenia (40–50%), 
hemolytic anemia (14–23%), renal disease that has only recently been recognized 
Inflammation
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as a consequence of APS, and Liveto redicularis [42–48]. Female patients with APS 
and kidney disease from antiphospholipid antibodies typically have high blood 
pressure, which is an additional serious risk to their pregnancy and can lead to the 
complications mentioned above [42–48].
20. When will we check a patient for aPLs
1. Spontaneous venous thrombosis at age <45 years (deep vein thrombosis,  
pulmonary embolism)
2. Arterial thrombosis in a person <45 years of age (myocardial infarction),  
without risk factors
3. Recurrent pregnancy loss
4. Thrombosis and vascular diseases associated with SLE
5. Recurrent thrombocytopenia of unknown etiology
6. Neurological manifestations
7. Acquired heart valve disease
8. Liveto redicularis
9. Patients with a false positive RPR test
10. Prolongation of any coagulation test [42–54].
Finally, for the presence of antiphospholipid syndrome, women of reproductive 
age who have any of the following characteristics should be screened (other than 
those mentioned above): False positive test for syphilis, stroke and venous throm-
bosis without other predisposing prolongation of aPTT, SLE and autoimmune 
hemolytic anemia [48–58].
Of course, from the medical history of the pregnant woman should always be 
sought the episodes of venous thrombosis that are usually observed in the veins 
of the lower extremities, which are not necessarily accompanied by episodes of 
pulmonary embolism, but also in rarer localizations, such as the sphenoid sinuses 
of the skull and the small visceral vessels. Autoantibodies and microthrombotic 
mechanisms could affect the normal implantation, the trophoblasts’ expansion and 
the development of effective fetoplacental circulation leading to abortions of the 
first trimester [48–58].
At older gestational ages endometrial death is attributed to massive placental 
thrombosis while the mechanisms associated with other complications (preeclamp-
sia) are unknown. In terms of laboratory findings, moderate to high IgG or IgM 
antibodies to cardiolipin (20–50 GPL, 20–80 MPL respectively) or lupus anticoagu-
lant should be detected [48–58].
Patients who present with clinical manifestations of APS could be permanently 
negative for the three main autoantibodies. Women with positive aPLs are more 
likely to have thromboembolic events, miscarriage or fetal death, intrauterine 
growth retardation, severe preeclampsia, and placental abruption. However, 
the presence of these antibodies cannot exclude the possibility of a successful 
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pregnancy and/or estimate the risk of potential complications. The existence of a 
burdensome obstetric or pathological history seems to play a more important role, 
since the reporting of thrombotic episodes, SLE or fetal death is associated with 
a 40% chance of premature birth and a greater than 30% chance of intrauterine 
growth retardation. From the beginning of pregnancy until the 20th week, visits 
should be made every 15 days and then every week until delivery [52–60].
Ultrasound examination of fetal development, but also the evaluation of the 
amount of amniotic fluid, should begin in the 16th week and be repeated every 
month unless there is a pathological finding. There is evidence that bilateral pres-
ence of notches in the uterine arteries, on Doppler screening at 24 weeks, can detect 
with satisfactory sensitivity those patients who develop preeclampsia and IUGR 
if they have a positive lupus anticoagulant. The umbilical artery test with Doppler 
from the 26th week until childbirth offers great help, while for the same period of 
time a weekly cardiotocographic test (non-stress test) should be performed, as well 
as an ultrasound control of the amount of amniotic fluid. The most commonly used 
regimen involves the administration of aspirin (80 mg daily) and heparin, either 
crystalline or low molecular weight, in prophylactic doses [60–64].
The patient’s health condition before pregnancy will determine the resumption 
of therapy after childbirth. Thus, two to three days after delivery, women taking 
coumarin derivatives before pregnancy (due to a history of a thromboembolic 
event) should discontinue heparin (after an INR of 2–2.5) and resume taking these 
drugs. To decrease the possibility of a new thromboembolic event, women with a 
thrombotic history during the late pregnancy should be treated with prophylactic 
doses of heparin or coumarin derivatives for 6 weeks postpartum. For women with-
out a thrombotic history, the anticoagulant therapy could be continued for the first 
five postpartum days at most. Compared to conventional heparin, less complica-
tions were related to low molecular weight heparins. Regarding the duration of the 
treatment, some recommend the prophylactic administration until the completion 
of the 37th week, then proposing induction of labor and others the administration 
until the automatic onset of labor with the simultaneous administration of vitamin 
K antagonists.
Hyperimmune γ-globin is no longer recommended because there is no clear 
evidence of improved perinatal outcome. Coumarin is not administered particularly 
in the 1st and 3rd trimesters as potential teratogens and due to easy passage through 
the placenta coagulation disorders in the fetus and because they are associated with 
greater maternal morbidity. Their administration is indicated only in rare cases of 
contraindication to heparin or aspirin [60–68].
Complications of anticoagulant therapy in pregnancy include embryopathy 
(nasal hypoplasia, spotted epiphyses), CNS abnormalities (Dandy-Walker syn-
drome, visual atrophy), fetal bleeding, hemorrhagic manifestations, skin allergies, 
thrombocytopenia and osteoporosis [60–72].
The basic principles of APS treatment include the systematic monitoring of 
the pregnant woman, the continuous assessment of the condition of the fetus, the 
administration of medication and the selection of the most appropriate time and 
manner of delivery. Despite the lack of large cross investigations, the usual thera-
peutic directions includes the corticosteroids, the aspirin, heparin, hyperimmune 
gamma globulin and coumarins.
Treatment should be applied only when the risk of complications is considered 
to be higher and after a thorough discussion with the pregnant woman. The prog-
nostic factors of poor outcome are the title of anticardiolipin antibodies and the 
obstetric history [60–72].
Aspirin significantly reduces the risk of thrombosis by blocking platelet 
aggregation. It is considered safe during pregnancy. Until now, there are no 
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final conclusions regarding the efficacy of the above therapy as monotherapy. 
Hydroxychloroquine inhibits aPL-B2GPI complexes on phospholipid surfaces, 
annexin A5, TF tissue factor, TLPs Toll-like receptors, statins such as pravastatin 
inhibition of Nuclear factor kappa B (NF-κB) is protein transcription factor, Anti-
CD20 monoclonal antibodies (mAbs) resistant APS and aspirin are recommended 
to prevent and treat preeclampsia [60–72].
The choice of time and method of delivery depends mainly on the presence or 
absence of complications of the disease during pregnancy. In any case of intra-
uterine suffocation of the fetus, induction of labor is required with all the possible 
harmful consequences of prematurity. In asymptomatic forms of the disease and 
when there are no signs of fetal difficulty, childbirth is preferred as much as pos-
sible at the end of pregnancy.
Worldwide, the route of delivery has been the subject of intense controversy 
and it is not clear if vaginal delivery or cesarean (c-)section is safer for the mother. 
Thus, prelabour c-section or vaginal delivery should be guided by obstetric criteria 
[60–72].
APS (primary or secondary) is a chronic systemic autoimmune disorder that 
mainly affects young women of childbearing age. APL can impair trophoblast func-
tion and can cause implantation failure by not allowing fusion of the cytotropho-
blast and can also developing small thrombophilia increase abortion rate. Natural 
killer cells attach to the cytotrophoblast of the embryo. However, the mechanisms 
by which such cells may or may not affect the embryo is not proven. Moreover, after 
the implantation, there is a slight inflammatory response. Patient with recurrent 
miscarriages and infertility develop less prominent reaction that may prevent the 
fetus from implantation [72–74].
21. Conclusion
The effect of the syndrome on pregnancy is accompanied by a multitude of 
serious complications that significantly increase the rates of maternal and especially 
perinatal morbidity and mortality.
There is an urgent need to create a new laboratory method, which will detect 
with great sensitivity and specificity all antiphospholipid antibodies and for this 
purpose large multicenter studies are already being done, the results of which are 
awaited.
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